Long Shortz with Island Pharmaceuticals: Safeguarding against dengue fever
Island Pharmaceuticals managing director updates on the company’s latest developments as it advances ISLA-101.
Stockhead
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News.
Tylah Tully speaks with Island Pharmaceuticals (ASX:ILA) managing director David Foster about the company's latest developments.
In January, the antiviral drug development company completed the enrolment of all subjects in the phase 2b arm of its ISLA-101 phase 2a/b PROTECT clinical trial in dengue fever.
Foster said Island is currently reviewing all the data before determining the next step.
This video was developed in collaboration with Island Pharmaceuticals, a Stockhead client at the time of publishing.
The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.
Originally published as Long Shortz with Island Pharmaceuticals: Safeguarding against dengue fever
Astral strikes more gold at Feysville
A 17-hole campaign at Kamperman in the Feysville project focused on infill drilling and tested multiple structural orientations, aiming to unlock the high-grade gold potential.
Read more
Dispelling private credit myths
As the once ‘alternative’ asset that is private credit becomes a portfolio staple, distinguishing risk from opportunity – and fact from fiction – remains a key challenge.
Read more